FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals recently reported past positive pivotal phase II results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva […]









